Global challenge aims to open new direction in breast cancer research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The California Breast Cancer Research Program has launched the Global Challenge to Prevent Breast Cancer, a competition designed to surface game-changing research ideas to advance breast cancer prevention.

CBCRP is seeking ideas from researchers, advocates, patients, activists, laypeople. The challenge is one of the signature commitments to the Biden Cancer Summit, the Biden Cancer Initiative’s nationwide effort to double the rate of progress against cancer.

By providing cash prizes, feedback from respected researchers, and the opportunity to present ideas to prominent leaders in the field, the challenge aims to unearth new and exciting ideas that people wished someone would explore, but thought might never get funded, have not had time to take on, or have not pursued yet for other reasons.

The challenge is unique in its focus on primary prevention. CBCRP is accepting applications in two categories: one for researchers and one for advocates.

Applicants can submit their ideas up until Jan. 7, 2019 at ToPreventBreastCancer.org. The most promising ideas will frame CBCRP’s future funding strategy and will be further developed in California with $15 million in grant funding.

Table of Contents

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login